Finance

Dawson James Securities initiates coverage of HIV vaccine developer

Published in Vaccine Weekly, October 1st, 2003

Robert Wasserman, director of Research for Dawson James Securities, a division of ViewTrade Financial, has initiated coverage on Immune Response Corporation (IMNR) with a buy rating and a 12-month price target of $8-$10.

Dawson James is a research-oriented healthcare/biotech boutique investment firm with offices in Florida and New Jersey.

IMNR, based in Carlsbad, California, is developing a therapeutic vaccine for the treatment of human immunodeficiency virus (HIV) infection. Currently, IMNR is focusing its research and development efforts on Remune, an immune-based therapy for HIV infection which was been the subject of over 18 clinical studies and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry